Musculoskeletal Diseases  >>  Agamree (vamorolone)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Agamree (vamorolone) / Santhera
2016-004262-26: A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy(DMD)

Completed
2
48
Europe, RoW
Vamarolone, Vamorolone, VBP15, Oral suspension
ReveraGen BioPharma Inc., ReveraGen BioPharma, Inc., ReveraGen BioPharma Inc., ReveraGen BioPharma, Inc.
Duchenne muscular dystrophy (DMD), Duchenne muscular dystrophy (DMD), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2016-004263-38: An Extension Study to Assess the Long-term Safety and Efficacy ofVamorolone in Boys With Duchenne Muscular Dystrophy(DMD)

Completed
2
48
Europe, RoW
Vamarolone, Vamorolone, VBP15, Oral suspension
ReveraGen BioPharma Inc., ReveraGen BioPharma, Inc., ReveraGen BioPharma Inc., ReveraGen BioPharma, Inc.
Duchenne muscular dystrophy (DMD), Duchenne muscular dystrophy (DMD), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2022-000844-31: Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy Studio del Vamorolone vs Placebo nel trattamento della Distrofia Muscolare di Becker

Not yet recruiting
2
39
Europe
vamorolone, [vamorolone], Oral drops, powder for suspension
ReveraGen BioPharma Inc., National Institute of health (NIH), Food and Drug administration (FDA), Foundation to Eradicate Duchenne (FED)
Becker Muscular Dystrophy Distrofia Muscolare di Becker (BMD), Becker Muscular Dystrophy Distrofia Muscolare di Becker (BMD), Diseases [C] - Musculoskeletal Diseases [C05]
 
 

Download Options